{
    "nct_id": "NCT03184870",
    "official_title": "A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Must have metastatic colorectal or pancreatic cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤1\n* Ability to swallow pills or capsules\n* Required to undergo mandatory pre and on-treatment biopsies\n* Adequate marrow function\n* Adequate other organ functions\n* Ability to comply with study visits, treatment, procedures, pharmacokinetic (PK) and pharmacodynamic (PD) sample collection, and required study follow-up\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Histology other than adenocarcinoma (neuroendocrine or acinar cell)\n* Suspected, known, or central nervous system (CNS) metastases (Imaging required only if participants are symptomatic)\n* Active, known or suspected autoimmune disease\n* Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration\n* Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity\n* Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor (PD-1), programmed death-ligand 1 [PD(L)-1] or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies\n* History of allergy to study treatments or any of its components of the study arm that participant is enrolling\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}